AUS
NZ
UK
CA
USA
IND
_06_04_2026_05_16_02_212823.jpg)
Highlights
- Extended SPP closing date to provide more participation time
- Strong trial results for lead CAR T-cell therapy program
- Expanded trial to cover new lymphoma subtypes
Imugene Ltd (ASX:IMU) has announced an extension to its Share Purchase Plan (SPP), now closing later in August, allowing eligible shareholders additional time to take part. The update follows encouraging clinical results from its lead allogeneic CAR T-cell therapy program, azer-cel.
The extension decision comes after feedback from investors seeking more time to assess the opportunity. The SPP, part of a wider capital raising effort, remains on the same terms as previously announced, with funds earmarked to advance azer-cel toward a pivotal Phase 2 trial.
While Imugene is not a constituent of the ASX 200, the company continues to draw attention for its research progress in the immuno-oncology space.
Clinical Progress Drives Momentum
Encouraging Trial Data
Recent trial updates have shown notable clinical responses in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These results included durable cancer-free outcomes for some individuals who had previously exhausted other treatment options.
Importantly, the trial has been expanded to include patients with rare and difficult-to-treat lymphoma subtypes, such as primary central nervous system lymphoma (PCNSL) and chronic lymphocytic leukaemia (CLL). These conditions currently lack approved CAR T-cell therapies, highlighting the potential impact of azer-cel in addressing unmet needs.
Innovative Therapeutic Approach
Azer-cel’s off-the-shelf design is intended to overcome the manufacturing delays and accessibility barriers often associated with traditional autologous CAR T-cell treatments. The therapy is also being trialed in combination with interleukin 2 (IL-2) to potentially improve treatment persistence and effectiveness.
Strengthened Position for Next Development Stage
With this extended timeline and recent capital raising, Imugene is positioned to progress its late-stage development plans for azer-cel while continuing to advance other programs within its pipeline. The extension also ensures broader shareholder engagement and aligns with the company’s strategy to maintain financial stability as it approaches pivotal trial milestones.
Frequently Asked Questions
- Why did Imugene extend the SPP closing date?
The company received feedback from investors requesting more time to participate following recent positive trial results. - What is azer-cel?
Azer-cel is an allogeneic CAR T-cell therapy designed to be immediately available without the lengthy manufacturing time of conventional approaches. - Which conditions are being targeted in the expanded trial?
The expanded trial includes patients with primary central nervous system lymphoma and chronic lymphocytic leukaemia, in addition to diffuse large B-cell lymphoma.
